

# The changes of platelets counts in atopic dermatitis patients after treatment of abrocitinib: a systematic review and meta-analysis

Suhua Wu<sup>1</sup>, Boyang Zhou<sup>1</sup>, Xueping Yue<sup>2</sup>, Linfeng Li<sup>1</sup>

<sup>1</sup>Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

<sup>2</sup>Department of Dermatology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Adv Dermatol Allergol 2024; XLI (2): 232–235

DOI: <https://doi.org/10.5114/ada.2024.138659>

Atopic dermatitis (AD) is a chronic inflammatory skin disease. Multiple immune cells and cytokines participate in the genesis of AD, such as Th2 cells, dendritic cells and interleukin (IL) 4 (IL-4), IL-5, IL-13, and IL-31 [1]. Abrocitinib is a selective JAK1 inhibitor that exerts its therapeutic effects by inhibiting downstream effects of the JAK-STAT pathway, suppressing the production of cytokines, such as IL-4, IL-13, and IL-31 [2, 3]. Clinical studies have shown efficacy of abrocitinib, while it also has some potential adverse effects, such as infections, and thrombocytopenia [3, 4]. In this study, we evaluated the changes of platelet counts after abrocitinib treatment through meta-analysis.

Publications were selected from six databases (Supplementary Figures S1 and S2, Table 1). The standardized mean difference (SMD) was used to assess the trends, aiming to eliminate the effects of differences in measurement units and methods. According to the between-study heterogeneity, the fixed or random effect model was applied. For each included study, the Newcastle-Ottawa scale (NOS) or the Cochrane bias evaluation tool was used to assess the study quality based on the study type.

A total of six Randomized Controlled Trials (RCT) were included (Supplementary Figure S3 shows the criteria). All the studies were considered as high-quality, because “low risk” and “unclear risk” were rated through the Cochrane bias evaluation tool. All the included studies reported the dose of 200 mg qd, while five reported 100 mg qd. The baseline levels of platelet counts were all considered as normal besides the 200 mg qd group in the study of Eichenfield 2021 (Table 1), and after treatment, all the counts remained normal. When abrocitinib was used with 100 mg qd, the numbers of platelets were decreased significantly at week 2, 4, 8, 12 and 16, with SMD =  $-0.46$  (95% CI:  $-0.57, -0.35$ );

$-0.72$  (95% CI:  $-0.82, -0.61$ );  $-0.54$  (95% CI:  $-0.64, -0.43$ );  $-0.40$  (95% CI:  $-0.51, -0.30$ ), respectively. At week 1 and 6, no significant changes were found. When abrocitinib was used with 200 mg qd, the numbers of platelets did not show significant change at week 1. Then, at week 2, 4, 6, 8, 12 and 16, significant decreases were shown, with SMD =  $-0.73$  (95% CI:  $-0.89, -0.56$ );  $-1.16$  (95% CI:  $-1.35, -0.97$ );  $-0.62$  (95% CI:  $-1.00, -0.23$ );  $-0.84$  (95% CI:  $-0.97, -0.70$ );  $-0.63$  (95% CI:  $-0.81, -0.45$ );  $-0.57$  (95% CI:  $-0.77, -0.38$ ), respectively (Figure 1, and Supplementary Figure S4).

We summarized the platelet count change trends over different weeks for both dose groups. For each dose group, the lowest point occurred at week 4, and as the treatment duration extended, the number of platelets showed an increasing trend. Compared to the 100 mg once daily dose group, patients receiving the 200 mg once daily treatment exhibited a more significant reduction. From the funnel plots, for both dose groups, the diagram showed asymmetry, which indicated that the results may not robust perfectly (Supplementary Figures S5).

Our study found that abrocitinib can cause a decrease in platelet counts in AD patients after treatment, with the lowest point at week 4 and then showing a tendency towards normal levels. Furthermore, we found that the dose of 200 mg qd had a more pronounced effect than the 100 mg qd, and this was similar to that observed in other RCTs [3]. The mechanism is not clear, yet may be mediated by the inhibition of JAK1 or through the inhibition of the Ashwell-Morell receptor and downstream effects on platelet production [5]. The limitations of our study: a relatively short period was observed, with at most 16 weeks; and in each comparison, the number of studies included was small, so no subgroup analysis was performed. Further well-designed studies with larger samples, focusing on a long-term treatment are needed.

**Address for correspondence:** Linfeng Li, Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, No.95 Yongan Road, Xicheng District, Beijing, 100050, China, phone: +86-10-63139108, fax: +86-10-63139259, e-mail: [zoonli@sina.com](mailto:zoonli@sina.com)  
**Received:** 6.10.2023, **accepted:** 20.11.2023, **online publication:** 25.04.2024.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>)


**Table 1.** Characteristics of included studies

Study ID	PMID	Type	Quality	Country	Severity	Age	Dose	Other treatment	Unit	Before treatment		After treatment		
										N	Level	Week	N	Level
Gooderham 2019	31577341	RCT	High	International	Moderate to severe	41.1 ±15.6	100 mg qd	Oral antihistamines were permitted	10 <sup>9</sup> /l	56	279.75 ±110.17	1	56	279.75 ±112.59
												2	56	257.25 ±104.54
												4	56	244.75 ±98.91
												6	56	254.25 ±101.33
												8	56	257.25 ±115.00
		12	56	269.00 ±131.08										
Simpson 2020	32711801	RCT	High	International	Moderate to severe	32.6 ±15.4	100 mg qd	Oral antihistamines were permitted	10 <sup>9</sup> /mm <sup>3</sup>	55	270.75 ±78.46	1	55	257.00 ±89.67
												2	55	223.25 ±90.47
												4	55	189.25 ±96.07
												6	55	216.75 ±94.47
												8	55	216.25 ±89.67
		12	55	238.75 ±120.09										
Bieber 2021	33761207	RCT	High	International	Moderate to severe	37.3 ±14.8	100 mg qd	Topical therapies were allowed	10 <sup>9</sup> /mm <sup>3</sup>	238	280.20 ±64.64	2	226	253.90 ±63.14
												4	228	231.90 ±61.91
												8	219	246.30 ±64.97
												12	221	257.90 ±68.09
												16	215	261.10 ±65.10

Table 1. Cont.

Study ID	PMID	Type	Quality	Country	Severity	Age	Dose	Other treatment	Unit	Before treatment		After treatment					
										N	Level	Week	N	Level			
Blauvelt 2021	34416294	RCT	High	International	Moderate to severe	29.0 [20.0, 41.0]	200 mg qd	—	10 <sup>3</sup> /mm <sup>3</sup>	226	277.60 ±66.90	2	220	231.90 ±61.26			
															4	221	201.50 ±57.98
															8	216	220.10 ±56.14
															12	207	234.20 ±54.67
16	203	241.50 ±58.27															
Eichenfield 2021	34406366	RCT	High	International	Moderate to severe	16.0 [14.0, 17.0]	100 mg qd	Topical therapy; oral antihistamines were permitted	10 <sup>3</sup> /μl	95	293.56 ±52.50	2	95	265.80 ±66.40			
															4	779	192.88 ±54.24
															8	786	216.60 ±59.25
															12	773	223.51 ±58.41
Silverberg 2022	32492087	RCT	High	International	Moderate to severe	37.4 ±15.8	100 mg qd	Oral antihistamines were permitted	10 <sup>3</sup> /μl	94	*302.75 ±71.03	2	94	254.59 ±77.20			
															4	94	227.36 ±75.68
															8	94	253.52 ±71.03
															12	94	265.45 ±61.77
Silverberg 2022	32492087	RCT	High	International	Moderate to severe	33.5 ±14.7	200 mg qd	Oral antihistamines were permitted	10 <sup>3</sup> /mm <sup>3</sup>	158	267.85 ±63.78	2	158	235.27 ±57.32			
															4	158	216.49 ±58.94
															8	158	227.51 ±65.40
															12	158	233.02 ±68.63
Silverberg 2022	32492087	RCT	High	International	Moderate to severe	33.5 ±14.7	200 mg qd	Oral antihistamines were permitted	10 <sup>3</sup> /mm <sup>3</sup>	155	252.97 ±65.41	2	155	218.24 ±70.26			
															4	155	191.84 ±58.14
															8	155	210.83 ±54.91
															12	155	219.26 ±61.37

\*Mean value over 300.



**Figure 1.** Changes of platelet counts after abrocitinib treatment at different weeks

In clinical practice, more attention should be paid to platelet-related conditions for patients receiving abrocitinib treatment. Furthermore, future research should be conducted to assess the applicability of abrocitinib in patients with platelet dysfunction.

### Acknowledgments

This study was supported by Beijing Municipal Natural Science Foundation (No. 7222037).

Suhua Wu and Boyang Zhou – first co-authors.

### Conflict of interest

The authors declare no conflict of interest.

### References

1. Ständer S. Atopic dermatitis. *N Engl J Med* 2021; 384: 1136-43.
2. Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. *JAMA Dermatol* 2019; 155: 1371-9.
3. Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. *J Dtsch Dermatol Ges* 2022; 20: 19-24.
4. Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. *Expert Rev Clin Immunol* 2022; 18: 233-44.
5. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. *Nat Med* 2015; 21: 47-54.